SOURCES SOUGHT
65 -- Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Wipes.
- Notice Date
- 2/26/2008
- Notice Type
- Sources Sought
- Contracting Office
- Great Plains Regional Contracting Ofc, ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200
- ZIP Code
- 78234-6200
- Solicitation Number
- DADA09-08-T9008
- Response Due
- 3/18/2008
- Archive Date
- 5/17/2008
- Point of Contact
- kevin.w.hill1, 210-292-3270
- E-Mail Address
-
Email your questions to Great Plains Regional Contracting Ofc
(kevin.w.hill1@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- A. General Information. The Central Region (6, 7 & 8), a military integrated delivery network, comprised of 42 Army, Navy, Air Force Medical Treatment Facilities (MTFs) in the states of Arizona, Arkansas, Colorado, Idaho, Kansas, Louisia na, Missouri, Oklahoma, Nebraska, Nevada, New Mexico, North Dakota, South Dakota, Texas, Utah, and Wyoming, announces a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Wipes. The primary objective of this prog ram is to standardize the quality of care across the region based on a best value determination that represents the clinically preferred product or source(s) at the best possible price. It is also intended that standardized products be obtained through th e DoD Prime Vendor Program. The major facilities in the region include but are not limited to Brooke Army Medical Center Fort Sam Houston TX, Wilford Hall Medical Center Lackland AFB, TX, Darnall Army Medical Center, Fort Hood, TX, Reynolds ACH Fo rt Sill, OK, William Beaumont Army Medical Center Fort Bliss, TX, 10th Medical Group USAF Academy, CO, Evans ACH Fort Carson CO, Fort Leonard Wood ACH, MO, Fort Riley, KS, 99th Medical Group Nellis AFB, NV, and Bayne-Jones ACH Fort Polk, LA. T his standardization action is part of the Medical/Surgical Prime Vendor program executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. In order to participate, your company must have a Distribution and Pricing Agreemen t (DAPA) and a separate commercial agreement with the Prime Vendor for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow Prime Vendors to distribute their products. This RFRIAQ is a su pplement to the Prime Vendor Program and is not a contract. For additional information regarding DSCPs Prime vendor program please access their web site at https://dmmonline.dscp.dla.mil The resulting Regional Incentive Agreement (RIA) will be for a base period of two years (24 months) from date of selection with three12-month option periods. Anticipated selection date is May 2008. The evaluation will be based on clinical, technical, and pricing factors. The Technical/Company and Clinical/Performa nce evaluation factors are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determined utilizing Best value/ trade-off criteria. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF preference and product availability. B. Products & Performance Required. The Central Region (6, 7 & 8) is seeking product line items in the category of Wipes, which at a minimum includes the high volume lines be low. Within this region, this product line has an estimated annual dollar requirement of $190,773.47. This forecast is based on historical prime vendor sales during a recent 12-month period. The top high volume usage lines for this project include: Di sposable Wipes Large (tub) $41,230.42; Baby Wipes $23,597.94; Dry Wipes $21,008.79. At the request of the Central Region (6, 7 & 8) MTFs, vendors will provide on-site support and in-servicing during implementation, educational resources and tools fo r clinical use of the product, conversion information, prime vendor order numbers, MSDS information, and itemization of the brands, types and packaging information of the products supplied by the vendor. C. Instructions to Vendors. INTEREST ED RESPONDENTS MUST PROVIDE DETAILED HARD COPY RESPONSES TO THE TECHNICAL CRITERIA REQUIREMENTS STATED WITHIN THIS NOTICE BY 3PM CST ON 18 March 2008. Vendors that fail to meet this submittal deadline will be disqualified from participating. This process will include vendor requirements to provide hard copy responses to technical criteria, no charge samples for clinical evaluation, and submission of ele ctronic best price quotes. Due to the potential for mail to be lost, vendors must confirm with the Regional POC stated below that their submission, quotes, and literature or other requested information has actually arrived at the Tri-Service Regional Busi ness Office (TRBO). Each submitting vendor will confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Responses should be sent via your preferred delivery carrier with a requested return receipt and/or tracking number to Ms. Sarah Allen, Tri-Service Regional Business Office, 7800 IH-10 West, Suite 220, San Antonio TX 78230. (ELECTRONIC SUBMISSIONS TO INITIAL ANNOUNCEMENT ARE NO LONGER ACCEPTED) Contact Ms. Sarah Allen at (210) 292-3287 prior to the closing date of this announcement with any further questions. D. Evaluation Criteria. The Tri-Service Product Review Board (TPRB) is the governing body of the standardization process. This board includes cli nicians and logisticians from the Military Treatment Facilities within the Central Region (6, 7 & 8). They are the deciding officials for this initiative. Phase I Technical/Company Evaluation Process. The TPRB has used market research to conf irm the availability of product groups which the Central Region (6, 7 & 8) DSL has selected for standardization. Interested respondents are to respond to this FBO announcement by mailing their intent to participate with hard copies of the following inform ation: company name, point of contact, address, phone number, fax, email address, announcement number, DAPA number and complete answers to the technical criteria to the above POC by the required response date. Vendors are required to meet/provide response s to the technical/company criteria stated below. All technical/company criteria are weighted equally. The responses will be reviewed under the purview of the CPT to determine the acceptability of each vendor. After the review of the technical/company cr iteria, those vendors who meet these criteria will be qualified/invited to participate in the clinical/performance evaluation. Acceptability for purposes of evaluation of technical/company criteria: Generally, responses to all questions in this sect ion demonstrate: (1) the business concern submitting the quote is a distributor or manufacturer of a complete line of the subject medical/surgical consumables; (2) based on the vendors responses, the evaluators have reasonable confidence that the line or products and/or services submitted meet the medical standards of care of the community, applicable to such products or services; (3) the vendor has or is obtaining a DAPA for the items (vendors that fail to have a DAPA will be disqualified); (4) the vendor has, or is obtaining, an agreement covering the items with Cardinal Health, the Prime Vendor for the region (vendors whose products are not available through the regional PV will be disqualified); (5) the vendor intends to provide discounts off DAPA for a ll products included in this standardization initiative (vendors that fail to provide a discount from DAPA will be disqualified); and (6) the vendors information provided is factually correct. Any misrepresentation of information will disqualify the vendo r from further consideration. Technical/Company Criteria: During the pre-source selection procedures, the CPT will validate/approve the equally weighted company/technical criteria outlined below: 1. Vendor must manufacture and/or distribute a complete product line of Wipes. A complete line of product is defined as the MTFs requirements for usage items in the product line. Usage items are defined in the Medical/Surgical Prime Vendor contract statement of work as DAPA items ordered at least once per month, and at least one unit per order. At a minimum, this includes: Disposable Wipes and Baby Wipes. Provide certification of all brands of this prod uct line that you manufacturer or distribute with the initial submittal. 2. Vendors must have a DAPA or be in the process of applying for a DAPA number for the Wipes product line. Provide the DAPA number or proof of the application process with the in itial submittal. (Note that vendors that fail to have a DAPA or show a lack of progress in obtaining a DAPA will be disqualified.) All e-mail communication between vendors and the region will be digitally signed by the issuer. 3. Vendors must have a separate agreement with the regional prime vendor, Cardinal Health for distribution in this Region and provide certification of this with the initial submittal. (Note that vendors whose products are not available through the regional PV will be disquali fied.) 4. Vendors must provide discounts off DAPA for all products included in this standardization initiative. (Note that vendors that fail to provide a discount from DAPA will be disqualified). Where lower FSS prices are available, DAPA holders are r equired by previous agreement to provide the FSS price as their DAPA price. Therefore, FSS prices do not represent discounts off the DAPA. 5. Vendors must provide electronic and hard copy pricing quotes and a competitive product cross-reference in the prescribed electronic Microsoft Excel format upon request. The vendors who meet the following technical/company criteria will be qualified/invited to participate in the clinical/performance evaluation process via e-mail communication with each vendor. Al l communications of significant milestones, such as invitations to participate, notices of disqualification, etc. must be digitally signed. 6. Vendor must provide educational tools and materials for Wipes as well as no cost samples for the evaluation. Describe your available company educational tools and material resources with the initial submittal. 7. Vendor must provide customer service via telephonic, onsite, website or email for regional facilities. Identify company resources and capabili ties for such support with the initial submittal. 8. Vendors must have a local vendor representative available in the region. Provide contact information, i.e. name, address, phone number, and e-mail address with the initial submittal. 9. Vendor wi ll provide MSDS product information. 10. Expiration date must appear on package. 11. Alcohol-free Baby Wipes must be available. 12. Baby Wipes must be available in scented and unscented. 13. Disposable Wipes literature must show kill rates and kill times of RSV, HBV, HIV-1, TB, MSRA, VRE, Staphyloccocus aeures and Salmonella. 14. Baby Wipes must be available with and without moisturizer. Phase II Clinical/Performance Evaluation Process. The multi-disciplinary Clinical Product Te am facilitated by the TRBO will request samples (at no charge to the government) from the product line to be clinically evaluated at select Military Treatment Facilities. Vendors are required to ship their no cost samples directly to the designated MTFs a nd will be allowed 21 calendar days from the date of notification to complete the delivery. Samples must be shipped to arrive at the MTF by COB, 3PM CST, on the (21st) calendar day after the notice to ship. Vendors failing to deliver by the deadline will be disqualified from further consideration in the standardization process. CPT teams will evaluate the product against the clinical/performance criteria in a clinical setting. All clinical/performance criteria are weighted equally. The clinical evaluation period is estimated to last approximately eight weeks. The CPT will evaluate the clinical/performance criteria using a Likert-like one to five rati ng scale where as: One (Does not meet minimum needs - worst score), Two (Meet minimum needs but is not clinically recommended), Three (Meet minimum needs), Four (Exceed minimum needs), Five (Provides superior clinical advantages - best score). The CPT has established a target threshold of 3.0 for the clinical acceptability of products for standardization. The CPT will analyze this acceptability as being at or near 3.0 depending on the break in the average scores and how closely scores are clustered near t he Acceptability Target Threshold of 3.0. Subject to this review, products below this threshold will be clinically unacceptable and be disqualified from further consideration for standardization. In the pre-source selection procedures above, the CPT will determine/approve that both product literature and sample sets are required for the evaluation. The CPT intends that clinical evaluations be conducted in a clinical setting; however, the Government reserves the right to conduct evaluations in ei ther a non-clinical or clinical setting or both. Clinical evaluations will be tabulated by the TRBO and results will be forwarded to the CPT for review. Clinical/Performance evaluation is more important than the price. Based on the clinical evaluation r esults, the CPT will provide a vendor selection recommendation to the TPRB. Clinical/Performance Criteria: During the pre-source selection procedures, the CPT will evaluate products based on the equally weighted clinical/performance criteria outli ned below: Clinical Acceptability Target Threshold: 3.0 1. Disposable Wipes are moist (having enough solution to clean area without leaving wet residue on the surface). 2. Disposable wipes are strong enough to prevent tearing during use (tearing or shredding wipe may cause incomplete contact and affect kill times). 3. Baby Wipes are thick and soft (allow for comfort to hands, face and buttocks and to avoid skin breakdown, patient comfort). Phase III Pricing Analysis Process. 1. The following elements will be considered in the pricing analysis: (1) Operational Impact of RIA prices on the Region (Post-Standardization Costs), (2) Potential Cost Avoidance, (3) Impact of Unmatched Lines, and (4) Impact on SKUs by each vendor. Due to the potential for Base DAPA prices to be inflated, the Impact of RIA prices on the Region is considered more important than other pricing elements. 2. Vendors that meet the 3.0 clinical acceptability target threshold will be qualified to su bmit best value pricing for analysis to the TRBO. Those vendors with results less than 3.0 will be disqualified from further consideration depending on the break in the average scores and how closely scores are clustered near the Acceptability Target Thre shold as determined by the CPT. Vendors that have been disqualified will be notified in writing at the conclusion of the evaluation process. 3. Vendors will be given 14 calendar days from the date of request to submit their best pricing quotes, in a prescribed format, based upon the total requirements of the Central Region (6, 7 & 8). The Region intends to evaluate quotes and select a vendor or vendor(s), without discussions. Vendor quotes should contain the vendors best product matches for the prod ucts or product lines requested in this announcement. Vendor quotes should contain the vendors best responses to all technical and/or company questions listed in this announcement. Vendor quotes should contain the vendors best tiered-pricing discounts of f of the vendors DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Region). Additionally, the Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down-selection is made during the evaluation process, the Region may limit the number of quotes to the greatest number that will permit an efficient competitio n among vendors. 4. Those vendors that fail to respond as required will be disqualified from further consideration. 5. Vendors will forward pricing to the TRBO, and the TRBO will prepare a pricing analysis. Pricing will be based on a committed volume for a two-year period with possible one-year option periods not to exceed a total of 5 years. 6. The Technical/Company and Clinical/Performance evaluation factors are considered significantly more important than cost or price. As the evaluation result s become more equal, price will become more important. 7. The Central Region (6, 7 & 8) TPRB reviews the data for a best value decision. 8. The DSL will ensure that the prices, with discounts off the Distribution and Pricing Agreement (DAPA) will b e a good value, in conjunction with the volume purchasing commitment, and the technical merit of the submittal. 9. The Central Region (6, 7 & 8) TPRB votes for the best value for a single or multiple vendor selection(s). The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF preference and product availability.
- Place of Performance
- Address: Great Plains Regional Contracting Ofc ATTN: MCAA GP L31 9V, 3851 Roger Brooke Drive Fort Sam Houston TX
- Zip Code: 78234-6200
- Country: US
- Zip Code: 78234-6200
- Record
- SN01517219-W 20080228/080226224337 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |